Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$24.79 USD

24.79
541,580

+0.82 (3.42%)

Updated Jul 25, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Prothena (PRTA) Stock Jumps 16.8%: Will It Continue to Soar?

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Why Is Prothena (PRTA) Up 46.8% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena's (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 7.23% and 80.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Prothena (PRTA) Q4 Earnings Expected to Decline

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Prothena (PRTA) Down 19.9% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates

Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.

Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -13.24% and -70.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) to Advance Parkinson's Disease Drug to Phase II

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

Prothena (PRTA) Up 2.9% Since Last Earnings Report: Can It Continue?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session

Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 1.67% and -37.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Down 24.8% Since Last Earnings Report: Can It Rebound?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Q4 Loss Narrower Than Expected, Revenues Beat

Prothena (PRTA) reports a narrower-than-expected Q4 loss, while revenues surpass estimates.

Options Traders Expect Huge Moves in Prothena (PRTA) Stock

Investors need to pay close attention to Prothena (PRTA) stock based on the movements in the options market lately.

Why Is Prothena (PRTA) Up 36.1% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3

Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.

Prothena (PRTA) Reports Q3 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 9.26% and 36.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Prothena (PRTA) Down 8.9% Since Last Earnings Report?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 28.57% and -22.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Prothena (PRTA) Report Negative Q2 Earnings? What You Should Know

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.